Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.

Who Optimizes SG&A Costs Better?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, MiMedx Group, Inc. and Viking Therapeutics, Inc. have shown contrasting strategies in optimizing these costs. From 2014 to 2023, MiMedx consistently reported higher SG&A expenses, peaking at over $258 million in 2018. In contrast, Viking Therapeutics maintained a leaner approach, with expenses rising from approximately $1.2 million in 2014 to $37 million in 2023. This represents a staggering 2,900% increase, reflecting their aggressive growth strategy. Meanwhile, MiMedx's expenses grew by about 133%, indicating a more stable expansion. These trends highlight the differing operational strategies of these companies, with MiMedx focusing on steady growth and Viking on rapid expansion. Understanding these dynamics offers valuable insights into their financial strategies and market positioning.